RE:RE:RE:Failure, again."In general 10 % of candidates get to market and this will probably be in 2035 - Gagnon says in 7 years - and also none of them might get there"
Avenanthramide has been tested in other human clinical trials and found safe. It is in oats. A synthetic analog of avenanthramide was approved in Japan with a strong safety profile. CZO has already run a human clinical trial with its avenanthramide at low doses in an exercise inflammation study and it was safe. CZO will be able to generate safety/tolerability data in its Phase I in the broader context of safety/tolerability data for avenanthramide and preliminary efficacy data in the approved Phase IIa clinical trial in patients with mild inflammation. It will be able to generate this data with little money and with the safety/tolerability and with preliminary efficacy data in hand license the technology to pharma if the results are promising. There are many potential applications for avenanthramide as a review of PubMed indicates. Given the addressable market a licensing deal with safety/tolerability and preliminary efficacy could be quite valuable.
"Published data has indicated that polyphenols, such as avenanthramides, may act as modifiers of signal transduction pathways, exhibiting beneficial effects. These natural compounds are known to express anti-inflammatory activity by modulating the expression of proinflammatory genes, including cyclo-oxygenase, lipoxygenase, nitric oxide synthases, and key cytokines. The AvenActive study will focus on evaluating biomarkers of inflammation in blood, with a particular emphasis on pro-inflammatory cytokines, chemokines, and other inflammatory markers such as high sensitivity C-reactive protein." News rlease